{"changeSha256":"d428e9fd21e40c668441fb98bc125c2e3360d5154644cef11256da8268e97101","changedAt":"2026-07-27","changedFields":[{"after":"A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.","before":"A glucagon/GLP-1 receptor agonist candidate with trial-registry records.","field":"Profile summary"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/pemvidutide/versions/2/","version":2},"id":"profile:pemvidutide:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.","peptideSlugs":["pemvidutide"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/pemvidutide/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"ctg-nct05989711-v10","name":"ClinicalTrials.gov","sourceClass":"A","title":"IMPACT: Pemvidutide in Participants With NASH · record history version 10 · last update posted 2026-05-18","url":"https://clinicaltrials.gov/study/NCT05989711?a=10&tab=history","verifiedAt":"2026-07-22"}],"subject":{"slug":"pemvidutide","type":"profile"}}